The role of sphingosine kinase isoforms and receptors S1P1, S1P2, S1P3, and S1P5 in primary, secondary, and recurrent glioblastomas

Tumor Biology

Volumn 35, Issue 9, 2014, Pages 8979-8989

  Quint, Karl ^a,e   Stiel, Norbert ^a   Neureiter, Daniel ^c   Schlicker, Hans Ulrich ^c   Nimsky, Christopher ^d   Ocker, Matthias ^a,f   Strik, Herwig ^d   Kolodziej, Malgorzata Anna ^b,d  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b UNIVERSITY HOSPITAL GIESSEN   (Germany)

^c Salzburger Landeskliniken   (Austria)

^d UNIVERSITY HOSPITAL MARBURG   (Germany)

^e UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^f BAYER PHARMA AG   (Germany)

Author keywords

Chemotherapy; Glioblastoma multiforme; Radiation; Sphingosine kinase; Sphingosine 1 phosphate receptors

Indexed keywords

ANTINEOPLASTIC AGENT; ISOPROTEIN; MESSENGER RNA; SPHINGOSINE 1 PHOSPHATE 1 RECEPTOR; SPHINGOSINE 1 PHOSPHATE 2 RECEPTOR; SPHINGOSINE 1 PHOSPHATE 3 RECEPTOR; SPHINGOSINE 1 PHOSPHATE 5 RECEPTOR; SPHINGOSINE 1 PHOSPHATE RECEPTOR; SPHINGOSINE KINASE; SPHINGOSINE KINASE 1; SPHINGOSINE KINASE 2; UNCLASSIFIED DRUG; ISOENZYME; PHOSPHOTRANSFERASE; S1PR1 PROTEIN, HUMAN; S1PR2 PROTEIN, HUMAN; SPHINGOSINE-1-PHOSPHATE RECEPTOR-3, HUMAN;

ADJUVANT CHEMORADIOTHERAPY; ADULT; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CELL GROWTH; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; PRIMARY TUMOR; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; SECOND CANCER; SIGNAL TRANSDUCTION; SURVIVAL TIME; AGED; BRAIN; CHEMORADIOTHERAPY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PROCEDURES; RADIATION RESPONSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SECONDARY; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BRAIN; CHEMORADIOTHERAPY; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; ISOENZYMES; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); RECEPTORS, LYSOSPHINGOLIPID; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84919845538     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1007/s13277-014-2172-x     Document Type: Article

References (40)

1. Maher EA, Furnari FB, Bachoo RM, Rowitch DH, Louis DN, Cavenee WK, et al. Malignant glioma: genetics and biology of grave matter. Genes Dev. 2001;15:1311–33.
2. Ocker M, Tackenberg B, Strik H. Fingolimod—development of signal transduction inhibitors for the therapy of multiple sclerosis. Nervenheilkunde. 2011;30(5):345–9.
3. Spiegel S, Milstien S. Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat Rev Mol Cell Biol. 2003;4(5):397–407.
4. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–96.
5. Anelli V, Gault CR, Snider AJ, Obeid LM. Role of sphingosine kinase-1 in paracrine/transcellular angiogenesis and lymphangiogenesis in vitro. FASEB J. 2010;24(8):2727–38.
6. Anliker B, Chun J. Cell surface receptors in lysophospholipid signaling. [Review]. Semin Cell Dev Biol. 2004;15(5):457–65.
7. Nishimura H, Akiyama T, Irei I, Hamazaki S, Sadahira Y. Cellular localization of sphingosine-1-phosphate receptor 1 expression in the human central nervous system. J Histochem Cytochem. 2010;58(9):847–56.
8. Estrada-Bernal A, Lawler SE, Nowicki MO, Ray Chaudhury A, Van Brocklyn JR. The role of sphingosine kinase-1 in EGFRvIII-regulated growth and survival of glioblastoma cells. J Neuro Oncol. 2011;102(3):353–66.
9. Estrada-Bernal A, Palanichamy K, Ray Chaudhury A, Van Brocklyn JR. Induction of brain tumor stem cell apoptosis by FTY720: a potential therapeutic agent for glioblastoma. Neuro Oncol. 2012;14(4):405–15.
10. Miron VE, Jung CG, Kim HJ, Kennedy TE, Soliven B, Antel JP. FTY720 modulates human oligodendrocyte progenitor process extension and survival. Ann Neurol. 2008;63(1):61–71.
11. Miron VE, Schubart A, Antel JP. Central nervous system-directed effects of FTY720 (fingolimod). J Neurol Sci. 2008;274(1–2):13–7.
12. Sonoda Y, Yamamoto D, Sakurai S, Hasegawa M, Aizu-Yokota E, Momoi T, et al. FTY720, a novel immunosuppressive agent, induces apoptosis in human glioma cells. Biochem Biophys Res Commun. 2001;281(2):282–8.
13. Maceyka M, Sankala H, Hait NC, Le Stunff H, Liu H, Toman R, et al. SphK1 and SphK2, sphingosine kinase isoenzymes with opposing functions in sphingolipid metabolism. J Biol Chem. 2005;280(44):37118–29.
14. Van Brocklyn JR, Jackson CA, Pearl DK, Kotur MS, Snyder PJ, Prior TW. Sphingosine kinase-1 expression correlates with poor survival of patients with glioblastoma multiforme: roles of sphingosine kinase isoforms in growth of glioblastoma cell lines. J Neuropathol Exp Neurol. 2005;64(8):695–705.
15. Young N, Van Brocklyn JR. Roles of sphingosine-1-phosphate (S1P) receptors in malignant behavior of glioma cells. Differential effects of S1P2 on cell migration and invasiveness. Exp Cell Res. 2007;313(8):1615–27.
16. Azuma H, Isaka Y, Nomi H, Inamoto T, Li XK, Hounig T, et al. Induction of donor-specific tolerance using superagonistic CD28 antibody in rat renal allografts: regulatory T-cell expansion before engraftment may be important. Transplantation. 2010;90(12):1328–35.
17. Hung JH, Lu YS, Wang YC, Ma YH, Wang DS, Kulp SK, et al. FTY720 induces apoptosis in hepatocellular carcinoma cells through activation of protein kinase C delta signaling. Cancer Res. 2008;68(4):1204–12.
18. Mousseau Y, Mollard S, Faucher-Durand K, Richard L, Nizou A, Cook-Moreau J, et al. Fingolimod potentiates the effects of sunitinib malate in a rat breast cancer model. Breast Cancer Res Treat. 2012;134(1):31–40.
19. Permpongkosol S, Wang JD, Takahara S, Matsumiya K, Nonomura N, Nishimura K, et al. Anticarcinogenic effect of FTY720 in human prostate carcinoma DU145 cells: modulation of mitogenic signaling, FAK, cell-cycle entry and apoptosis. Int J Cancer. 2002;98(2):167–72.
20. Shah MV, Zhang R, Irby R, Kothapalli R, Liu X, Arrington T, et al. Molecular profiling of LGL leukemia reveals role of sphingolipid signaling in survival of cytotoxic lymphocytes. Blood. 2008;112(3):770–81.
21. Wang JD, Takahara S, Nonomura N, Ichimaru N, Toki K, Azuma H, et al. Early induction of apoptosis in androgen-independent prostate cancer cell line by FTY720 requires caspase-3 activation. Prostate. 1999;40(1):50–5.
22. Ley R, Balmanno K, Hadfield K, Weston C, Cook SJ. Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim. J Biol Chem. 2003;278(21):18811–6.
23. Luciano F, Jacquel A, Colosetti P, Herrant M, Cagnol S, Pages G, et al. Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function. Oncogene. 2003;22(43):6785–93.
24. Vessey DA, Kelley M, Zhang J, Li L, Tao R, Karliner JS. Dimethylsphingosine and FTY720 inhibit the SK1 form but activate the SK2 form of sphingosine kinase from rat heart. J Biochem Mol Toxicol. 2007;21(5):273–9.
25. Brinkmann V. Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol Ther. 2007;115(1):84–105.
26. Meno-Tetang GM, Li H, Mis S, Pyszczynski N, Heining P, Lowe P, et al. Physiologically based pharmacokinetic modeling of FTY720 (2-amino-2[2-(-4-octylphenyl)ethyl]propane-1,3-diol hydrochloride) in rats after oral and intravenous doses. Drug Metab Dispos. 2006;34(9):1480–7.
27. Li J, Guan HY, Gong LY, Song LB, Zhang N, Wu J, et al. Clinical significance of sphingosine kinase-1 expression in human astrocytomas progression and overall patient survival. Clin Cancer Res. 2008;14:6996–7003.
28. Abuhusain HJ, Matin A, Qiao Q, Shen H, Kain N, Day BW et al. A metabolic shift favouring sphingosine 1-phosphate at the expense of ceramide controls glioblastoma angiogenesis. J Biol Chem. 2013 (Epub ahead of print).
29. Zhang H, Li W, Sun S, Yu S, Zhang M, Zou F. Inhibition of sphingosine kinase 1 suppresses proliferation of glioma cells under hypoxia by attenuating activity of extracellular signal-regulated kinase. Cell Prolif. 2012;45(2):167–75.
30. Kapitonov D. Targeting sphingosine kinase 1 inhibits Akt signaling, induces apoptosis, and suppresses growth of human glioblastoma cells and xenografts. Cancer Res. 2009;69(17):6915–23.
31. Olivera A, Rosenfeldt HM, Bektas M, Wang F, Ishii I, Chun J, et al. Sphingosine kinase type 1 induces G12/13-mediated stress fiber formation, yet promotes growth and survival independent of G protein-coupled receptors. J Biol Chem. 2003;278(47):46452–60.
32. Giussani P, Brioschi L, Bassi R, Riboni L, Viani P. Phosphatidylinositol 3-kinase/AKT pathway regulates the endoplasmic reticulum to Golgi traffic of ceramide in glioma cells: a link between lipid signaling pathways involved in the control of cell survival. J Biol Chem. 2009;284(8):5088–96.
33. Hannun YA, Obeid LM. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol. 2008;9(2):139–50.
34. Albulescu R, Codrici E, Popescu ID, Mihai S, Necula LG, Petrescu D, et al. Cytokine patterns in brain tumour progression. Mediat Inflamm. 2013;2013:979748.
35. Sen E. Targeting inflammation-induced transcription factor activation: an open frontier for glioma therapy. Drug Discov Today. 2011;16(23–24):1044–51.
36. Yoshida Y, Nakada M, Sugimoto N, Harada T, Hayashi Y, Kita D, et al. Sphingosine-1-phosphate receptor type 1 regulates glioma cell proliferation and correlates with patient survival. Int J Cancer. 2010;126(10):2341–52.
37. Wang F, Flanagan J, Su N, Wang LC, Bui S, Nielson A, et al. RNAscope: a novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues. J Mol Diagn. 2012;14(1):22–9.
38. Rex K, Jeffries S, Brown ML, Carlson T, Coxon A, Fajardo F, et al. Sphingosine kinase activity is not required for tumor cell viability. PLoS One. 2013;5:8(7).
39. Bektas M, Johnson SP, Poe WE, Bigner DD, Friedman HS. A sphingosine kinase inhibitor induces cell death in temozolomide resistant glioblastoma cells. Cancer Chemother Pharmacol. 2009;64(5):1053–8.
40. Guillermet-Guibert J. Targeting the sphingolipid metabolism to defeat pancreatic cancer cell resistance to the chemotherapeutic gemcitabine drug. Mol Cancer Ther. 2009;8(4):809–20.